Skip to main content

Table 1 Clinical details

From: Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

  CD Total CD Rem CD Res CD NRes Control
Characteristics n = 49 n = 29 n = 11 n = 9 n = 37
Gender (male/female) 22/27 15/14 4/7 3/6 18/19
Age, years (mean, range) 40 (19–71) 39 (22–62) 42 (20–63) 42 (19–58) 42 (26–63)
Age at diagnosis (≤25/> 25 years) 26/23 15/14 7/4 4/5
Years with disease (≤10/> 10 years) 27/22 16/13 6/5 5/4
HB-score (mean, range) 10 (6–18)a 10 (6–18)c 11 (8–15) 11 (5–15)f
PDAI (mean, range) 10 (2–12)b 9 (2–12)d 10 (9–12)e 7(6–9)g
Extension (D, J, TI, IC, C) 1, 1, 17, 5, 35 0, 0, 9, 3, 23 0, 0, 6, 1, 7 1, 1, 2, 1, 5
Surgery (IR, IR + HC, HC, Co, IC + Co) 9, 1, 2, 9, 4 5, 0, 2, 5, 0 2, 1, 0, 2, 2 2, 0, 0, 2,2
Smoking/non-smoking 13/36 11/18 1/10 1/8 0/37
EIM (present/not present) 4/45 1/28 2/9 1/8
Steroids, n     
Independent/dependent/responder/unknown 7/20/8/14 4/12/3/10 2/4/2/3 1/4/3/1
Daily medication, n     
Systemic 5-aminosalicylic acid (1.6–3.2 g) 2 1 0 1
Topical 5-aminosalicylic acid (1 g) 0 0 0 0
Systemic glucocorticoids (75 mg)h 9 6 2 1
Topical glucocorticoids (100 mg) 1 1 0 0
Azathioprine (100–150 mg) 29 18 7 4
Methotrexate (25 mg/wk) 1 0 0 1
None 15 9 4 2 37
  1. aSix patients had no luminal activity, only perianal fistulas
  2. bIn all, fourteen patients had perianal fistulas
  3. cFour patients had no luminal activity, only perianal fistulas
  4. dIn all, seven patients had perianal fistulas
  5. eThree patients had perianal fistulas
  6. fOne patient had no luminal activity, only perianal fistulas
  7. gIn all, three patients had perianal fistulas
  8. hTappering regime
  9. C colonic, Co colectomy, D duodenal, EIM extra-intestinal manifestations, HB Harvey–Bradshaw, HC hemicolectomy, IC ileocecal, IR ileocecal resection, J jejunal, NRes non-responder, PDAI perianal disease activity index, Rem remission, Res responder, TI terminal ileum